Widely used:Recently Viewed
Clear All$5.72
$0.09
(1.60%)
As on 23-Apr-2025 14:41EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$2,211 Mln
P/E Ratio
--
P/B Ratio
2.14
Industry P/E
--
Debt to Equity
0.1
ROE
-0.62 %
ROCE
-55.95 %
Div. Yield
0 %
Book Value
3.78
EPS
-1.69
CFO
$-632.36 Mln
EBITDA
$-864.46 Mln
Net Profit
$-895.97 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Recursion Pharmaceuticals Inc. Class A (RXRX)
| -15.38 | -14.37 | -23.63 | -24.74 | -1.58 | -- | -- |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Recursion Pharmaceuticals Inc. Class A (RXRX)
| -31.23 | 27.89 | -54.99 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.73 | 9,808.03 | 20.22 | 23.13 | |
| 284.42 | 8,956.09 | 22.08 | 58.42 | |
| 26.83 | 9,559.25 | -- | -28.77 | |
| 103.38 | 10,030.35 | 30.81 | 14.16 |
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to... industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Address: 41 South Rio Grande Street, Salt Lake City, UT, United States, 84101 Read more
Co-Founder, CEO & Director
Dr. Christopher C. Gibson Ph.D.
Co-Founder, CEO & Director
Dr. Christopher C. Gibson Ph.D.
Headquarters
Salt Lake City, UT
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Recursion Pharmaceuticals Inc Class A (RXRX) stood at $ 1,449 Mln as on 31-Dec-24
The share price of Recursion Pharmaceuticals Inc Class A (RXRX) is $5.72 (NASDAQ) as of 23-Apr-2025 14:41 EDT. Recursion Pharmaceuticals Inc Class A (RXRX) has given a return of -1.58% in the last 3 years.
Recursion Pharmaceuticals Inc Class A (RXRX) has a market capitalisation of $ 2,211 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Recursion Pharmaceuticals Inc Class A (RXRX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Recursion Pharmaceuticals Inc Class A (RXRX) and enter the required number of quantities and click on buy to purchase the shares of Recursion Pharmaceuticals Inc Class A (RXRX).
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Address: 41 South Rio Grande Street, Salt Lake City, UT, United States, 84101
The CEO & director of Dr. Christopher C. Gibson Ph.D.. is Recursion Pharmaceuticals Inc Class A (RXRX), and CFO & Sr. VP is Dr. Christopher C. Gibson Ph.D..
There is no promoter pledging in Recursion Pharmaceuticals Inc Class A (RXRX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Recursion Pharmaceuticals Inc. Class A (RXRX) | Ratios |
|---|---|
|
Return on equity(%)
|
-61.89
|
|
Operating margin(%)
|
-787.26
|
|
Net Margin(%)
|
-788.02
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Recursion Pharmaceuticals Inc Class A (RXRX) was $0 Mln.
